INO

1.7552.63%
WL

Wendy L. Yarno

Lead Independent Director

Ms. Wendy L. Yarno, MBA has been an Independent Director at IDEAYA Biosciences, Inc. since December 17, 2019. She served as Independent Director at Iovance Biotherapeutics, Inc. since April 18, 2023 until June 10, 2026. She served as an Independent Director of Global Blood Therapeutics Inc until October 05, 2022. Ms. Yarno serves as an Independent Director at Tarsus Pharmaceuticals, Inc. since November 2020 and serves as its Lead Independent Director since December 02, 2022. Ms. Yarno has vast experience in the biopharmaceutical industry. She serves as Member of New Media Advisory Board at Rally Health, Inc. Ms. Yarno retired in September 2008 from Merck & Co., Inc., where she spent in commercial and human resource positions of increasing seniority, including most recently as Executive Vice President and Chief Marketing Officer. She also served as general manager, Cardiovascular/Metabolic U.S. Business Unit and as Executive Vice President, Worldwide Human Health Marketing. and as Merck’s senior vice president of human resources. Earlier in her career, she was vice president of the Women’s Health Care Franchise for Johnson & Johnson’s Ortho McNeil Pharmaceutical subsidiary. From September 2010 to September 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno is a Director of Inovio Pharmaceuticals, Inc. since December 6, 2017. Ms. Yarno has served as a Member of the board of several public and private biotechnology and medical device companies, including ADial Pharmaceuticals, Durata Therapeutics and Plurogen Therapeutics. She previously served as a director of St. Jude Medical, Inc., since 2002 until January 2017. Ms. Yarno retired in September 2008 from Merck & Company, Inc. following a career in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer before she retired. Ms. Yarno served as the Director at Medivation. She served as Chairperson of the board of Aratana Therapeutics, Inc. since August 2015 and its Director since October 2013. She had been a Member of the boards of Alder Biopharmaceuticals until October 22, 2019 and was Director at MyoKardia, Inc. since March 2017 until November 16, 2020. She has extensive experience in commercialization of pharmaceutical products and in human resource management in the pharmaceutical industry and has service on the boards of multiple life sciences companies. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business and a B.S. in Business Administration from Portland State University.

Positions